<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Modulation of purinergic signaling, which is critical for vascular homeostasis and the response to vascular injury, is regulated by hydrolysis of proinflammatory ATP and/or <z:chebi fb="13" ids="16761">ADP</z:chebi> by ectonucleoside <z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi> diphosphohydrolase 1 (ENTPD-1; CD39) to <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>, which then is hydrolyzed by ecto-5'-nucleotidase (CD73) to <z:chebi fb="3" ids="16335">adenosine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We report here that compared with littermate controls (<z:mp ids='MP_0002169'>wild type</z:mp>), transgenic mice expressing human ENTPDase-1 were resistant to the formation of an occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> after FeCl(3)-induced carotid artery injury </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment of mice with the nonhydrolyzable <z:chebi fb="13" ids="16761">ADP</z:chebi> analog, <z:chebi fb="3" ids="16335">adenosine</z:chebi>-5'-0-(2-thiodiphosphate) trilithium salt, <z:chebi fb="110" ids="16335">Ado</z:chebi>-5'-PP[S], negated the protection from <z:mp ids='MP_0005048'>thrombosis</z:mp>, consistent with a role for <z:chebi fb="13" ids="16761">ADP</z:chebi> in platelet recruitment and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="3" pm="."><plain>ENTPD-1 expression decreased whole-blood aggregation after stimulation by <z:chebi fb="13" ids="16761">ADP</z:chebi>, an effect negated by <z:chebi fb="3" ids="16335">adenosine</z:chebi>-5'-0-(2-thiodiphosphate) trilithium salt, <z:chebi fb="110" ids="16335">Ado</z:chebi>-5'-PP[S] stimulation, and limited the ability to maintain the platelet fibrinogen receptor, <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> α(IIb)/β(3), in a fully activated state, which is critical for <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="4" pm="."><plain>In vivo treatment with a CD73 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, a nonselective <z:chebi fb="3" ids="16335">adenosine</z:chebi>-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, or a selective A(2A) or A(2B) <z:chebi fb="3" ids="16335">adenosine</z:chebi>-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, negated the resistance to <z:mp ids='MP_0005048'>thrombosis</z:mp> in transgenic mice expressing human ENTPD-1, suggesting a role for <z:chebi fb="3" ids="16335">adenosine</z:chebi> generation and engagement of <z:chebi fb="3" ids="16335">adenosine</z:chebi> receptors in conferring in vivo resistance to occlusive <z:mp ids='MP_0005048'>thrombosis</z:mp> in this model </plain></SENT>
<SENT sid="5" pm="."><plain>In summary, our findings identify ENTPDase-1 modulation of purinergic signaling as a key determinant of the formation of an occlusive <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> after vascular injury </plain></SENT>
</text></document>